{"url_path":"/sec/hcwb/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-024850-index.html","accession_number":"0001493152-26-024850","cik":"0001828673","ticker":"HCWB","issuer_name":"HCW Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-024850-index.html","primary_entity_key":"0001828673","primary_entity_name":"HCW Biologics Inc."},"word_count":141,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n4.1\n \n[Form of Pre-Funded Common Stock Purchase Warrant](ex4-1.htm)\n\n4.2\n \n[Form of Common Stock Purchase Warrant](ex4-2.htm)\n\n10.1\n \n[Form of Securities Purchase Agreement by and between the Company and the Investors](ex10-1.htm)\n\n10.2\n \n[Form of Registration Rights Agreement by and between the Company and the Investors](ex10-2.htm)\n\n10.3\n \n[Form of Placement Agency Agreement, by and between the Company and E.F. Hutton & Co. LLC](ex10-3.htm)\n\n99.1\n \n[Press Release dated May 21, 2026.](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n \n**HCW\nBIOLOGICS INC.**\n\n \n \n \n \n\nDate:\nMay\n21, 2026\nBy:\n*/s/\nHing C. Wong*\n\n \n \n \nHing\nC. Wong, Founder and Chief Executive Officer"}